A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia

Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data

M Othus;G Garcia-Manero;J Godwin;J Weick;F Appelbaum;H Erba;E Estey Haematologica Jan 1;108(1):42-47

PMid: PMID35833298 | PMC number: PMC9827148

Associations Between Complete Remission and 2-3 Year Survival Following 7+3 Induction for Acute Myeloid Leukemia

M Othus;G Garcia-Manero;J Godwin;J Weick;D Stirewalt;F Appelbaum;H Erba;E Estey Leukemia & Lymphoma, Aug;62(8):1967-1972; Mar 10;1-6. doi: 10.1080/10428194.2021.1885663. Online ahead of print.2021

PMid: PMID3719833

Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

J Naru;M Othus;C Lin;A Moseley;A List;C Willman;E Pogosova-Agadjanyan;F Wu;F Appelbaum;H Erba;I-M Chen;I Jenkins;J Kennedy;J Delrow;J Whiteaker;J Radich;J Godwin;L Beppu;M Fitzbiggon;M Fang;P Wang;P Gafken;R Ivey;S Meshinchi;T Chauncey;T Lorentzen;U Voytovich;A Paulovich;D Stirewalt American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #522

Global Proteomic Profiling Identifies Novel Prognostic Biomarkers in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A First-Of-Its-Kind Report Form the Fred Hutch and SWOG

D Stirewalt;M Othus;Y Naru;J Kennedy;E Pogosova-Agadjanyan;F Appelbaum;L Beppu;T Chauncey;J Delrow;H Erba;P Gafken;J Godwin;M Fitzgibbons;X Hua;I Jenkins;M Fang;R Ivey;C Lin;T Lorentzen;A Moseley;J Radich;J Voytovich;P Wang;J Whiteaker;C Willman;F Wu;S Meshinchi;A Paulovich American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #799

Second Cycle Remission Achievement with 7+3 and Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

M Othus;E Estey;G Garcia-Manero;BL Wood;D Stirewalt;J Godwin;J Weick;J Anderson;F Appelbaum;H Erba;R Walter Leukemia Feb;33(2):554-558; Oct 12. doi: 10.1038/s41375-018-0274-y. [Epub ahead of print]

PMid: PMID30315233 | PMC number: PMC6367002

Increasing lengths of first complete remission with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data

M Othus;G Garcia-Manero;JE Godwin;JK Weick;F Appelbaum;H Erba;E Estey Blood (2019) 134 (Supplement_1): 291, abst 613 (American Society of Hematology Annual Meeting (Dec 7-10, 2019, Orlando, FL), oral

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

2nd Cycle Remission Achievement with 7+3 is Associated with Shorter Survival in Adults with Newly Diagnosed Acute Myeloid Leukemia: Analysis of Recent SWOG Trials

M Othus;E Estey;G Garcia-Manero;B Wood;DL Stirewalt;J Godwin;J Weick;J Anderson;F Appelbaum;H Erba;R Walter Blood 132:3978; American Society of Hematology Annual Meeting (Dec 1-4, 2018, San Diego, CA), poster

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials

X Qu;M Othus;J Davison;Y Wu;L Yan;E Estey;J Radich;H Erba;F Appelbaum;M Fang Cancer Jul 1;123(13):2472-2481; 2017 Feb 21[Epub ahead of print]

PMid: PMID28222251; PMC5705230

Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival (“Potential Cure”) Over the Past Four Decades: Analysis SWOG Trial Data

M Othus;G Garcia-Manero;JE Godwin;J Weick;JE Anderson;DL Stirewalt;F Appelbaum;HP Erba;EH Estey Blood 2017 130:1301; American Society of Hematology Annual Meeting (December 9-12, 2017, Atlanta, GA), poster

Prediction of CR following a second course of "7+3" in patients with newly diagnosed acute myeloid leukemia not in CR after a first course

M Othus;S Mukherjee;MA Sekeres;JE Godwin;SH Petersdorf;F Appelbaum;H Erba;E Estey Leukemia Aug;30(8):1779-1780; 2016 Feb 29 [Epub ahead of print]

PMid: PMID27055872 | PMC number: PMC4980556

Resistance prediction in AML: analysis of 4,601 patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;B Lowenberg;H Kantarjian;G Ossenkoppele;R Hills;F Ravandi;A Evans;SA Pierce;F Appelbaum;E Estey Leukemia 29(2):312-320

PMid: PMID25113226 | PMC number: PMC4318722

Prognostic methylation markers for survival in cytogenetically normal AML patients treated on SWOG trials

X Qu;M Othus;J Davison;L Yan;E Estey;J Radich;H Erba;F Appelbaum;M Fang Blood 126(23):688; American Society of Hematology Annual Meeting (Dec 5-8, 2015, Orlando, FL), oral presentation;

Unsuccessful cytogenetic analysis is a poor prognostic feature in acute myeloid leukemia

B Medeiros;M Othus;E Estey;M Fang;F Appelbaum British Journal of Haematology 28(2):245-250;

PMid: PMID24383844 | PMC number: PMC4117470

Declining rates of treatment-related mortality in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Leukemia 28(2):289-292;

PMid: PMID23760400 | PMC number: PMC4457325

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials

WG Woods;AR Franklin;TA Alonzo;RB Gerbing;KA Donohue;M Othus;J Horan;FR Appelbaum;EH Estey;CD Bloomfield;RA Larson Cancer 119(23):4170-4179;

PMid: PMID24104597 | PMC number: PMC3833872

Significance of FAB subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients

RB Walter;M Othus;A Burnett;B Lowenberg;H Kantarjian;GJ Ossenkoppele;RK Hills;K van Montfort;F Ravandi;A Evans;SA Pierce;F Appelbaum;EH Estey Blood 121(13):2424-2431;

PMid: PMID23325837 | PMC number: PMC3612855

Prediction of CR on reinduction in patients with newly diagnosed acute myeloid leukemia given intensive induction regimens: a report from SWOG and Cleveland Clinic

M Othus;S Mukherjee;MA Sekeres;J Godwin;J Anderson;S Petersdorf;F Appelbaum;HP Erba;E Estey Blood 122:2686; American Society of Hematology meeting (Dec 7-10, 2013, New Orleans, LA), poster presentation;

Prediction of therapeutic resistance in adult acute myeloid leukemia: analysis of 4,550 newly diagnosed patients from MRC/NCRI, HOVON, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;AK Burnett;B Lowenberg;H Kantarjian;GJ Ossenkoppele;RK Hills;F Ravandi;A Evans;SA Pierce;F Appelbaum;E Estey Blood 122:64; American Society of Hematology annual meeting (Dec 7-10, 2013), oral;

Novel long-term co-culture approach identifies prognostically important heterogeneity of stem/progenitor cell involvement in human acute myeloid leukemia

GS Laszlo;JM Lionberger;BS Harrington;CJ Gudgeon;M Othus;F Appelbaum;ID Bernstein;R Walter Blood 122:1318; ASH annual meeting, poster presentaton

Impact of residual normal metaphases in core binding factor acute myeloid leukemia

B Medeiros;M Othus;M Fang;F Appelbaum;E Estey Cancer 118(9):2420-2423;

PMid: PMID21928314 | PMC number: PMC3490403

Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia

B Medeiros;M Othus;EH Estey;M Fang;F Appelbaum Haematologica 97(9):1401-1404

PMid: PMID22315487 | PMC number: PMCID3436242

Declining rates of treatment-related mortality recent in patients with newly-diagnosed AML given "intense" induction regimens: a report from SWOG and MD Anderson

M Othus;H Kantarjian;S Petersdorf;F Ravandi;J Godwin;J Cortes;S Pierce;H Erba;S Faderl;F Appelbaum;E Estey Blood 120(21):abst. 129; American Society of Hematology Annual Meeting, oral;

Prognostic significance of the French-American-British (FAB) morphologic subclassification of "acute myeloid leukemia, not otherwise specified" in the 2008 WHO classification: analysis of 5,848 newly diagnosed patients from HOVON, MRC, SWOG, and MD Anderson Cancer Center

R Walter;M Othus;AK Burnett;B Lowenberg;H Kantarjian;G Ossenkoppele;RK Hills;K van Montfort;F Ravandi;S Pierce;F Appelbaum;E Estey Blood 120(21)abst. 540; American Society of Hematology Annual Meeting, oral;

Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype [PMID21330329; PMC3069244]

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Haematologica 96(4):631-632

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation [PMID21680797;PMC3156042]

M Fang;B Storer;E Estey;M Othus;L Zhang;B Sandmaier;F Appelbaum Blood 118(6):1490-1494

Cytarabine dose for acute myeloid leukemia. (Letter to the Editor) [PMID21631340]

B Medeiros;M Othus;F Appelbaum New England Journal of Medicine 364(11):2167-2168

Prediction of early death following induction therapy for newly diagnosed acute leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

R Walter;M Othus;G Borthakur;F Ravandi;J Cortes;S Pierce;F Appelbaum;H Kantarjian;E Estey Journal of Clinical Oncology, 29(33):4417-23;

PMid: PMID21969499 | PMC number: PMC3221524

The effect of complete remission (CR) and CR with incomplete platelet recovery (CRp) on outcome in acute myeloid leukemia: a combined eastern cooperative oncology group (ECOG), Southwest Oncology Group (SWOG), and M.D. Anderson Cancer Center study

Journal of Clinical Oncology 28(10):1766-1771;

Prognostic impact of monosomal karyotype in young adults and elderly acute myeloid leukemia: the Southwest Oncology Group experience [PMID: 20562328; NIHMSID244631]

BC Medeiros;M Othus;M Fang;D Roulston;FR Appelbaum Blood 116(13):2224-2228

PMid: PMID20562328 | PMC number: PMC3709629

Outcome of adolescents and young adults (AYAs) with non-M3 acute myeloid leukemia (AML) treated on Children's Oncology Group (COG) trials compared to Cancer and Leukemia Group B (CALGB) and Southwest Oncology Group (SWOG) trials

A Franklin;T Alonzo;RB Gerbing;K Donohue;M Othus;J Horan;E Estey;RA Larson;WG Woods Blood 116:Abstract 183; poster

Influence of residual normal metaphases in patients with monosomal karyotype

B Xie;M Othus;B Medeiros;M Fang;F Appelbaum;E Estey Blood 116:Abstract 1671; ASH 2010 meeting; poster presentation

Very late antigen-4 (VLA-4) function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia [PMC2630271; PMID18927435]

PS Becker;KJ Kopecky;AN Wilks;JM Harlan;CL Willman;SH Petersdorf;T Papayannopoulou;FR Appelbaum Blood 113(4):866-874

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

FR Appelbaum;KJ Kopecky;MS Tallman;ML Slovak;HM Gundacker;HT Kim;GW Dewald;HM Kantarjian;SR Pierce;EH Estey British Journal of Haematology 135:165-173

Methylation profiling in acute myeloid leukemia

M Toyota;KJ Kopecky;MO Toyota;KW Jair;CL WIllman;JPJ Issa Blood 97(9):2823-2829

Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia

C Crump;C Chen;FR Appel baum;KJ Kopecky;SM Schwartz;CL Willman;ML Slovak;NS Weiss Cancer Epidemiology Biomarkers & Prevention 9:457-460

Acute myelogenous leukemia and aging. Clinical interactions.

JE Lancet;CL Willman;JM Bennett Hematology/Oncology Clinics of North America 14(1):251-267

Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia.

Q Li;KJ Kopecky;A Mohan;CL Willman;FR Appelbaum;JK Weick;JJ Issa Clinical Cancer Research 5:1077-1084

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-Glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group study

CP Leith;KJ Kopecky;IM Chen;L Eijdems;ML Slovak;TS McConnell;DR Head;J Weick;MR Grever;FR Appelbaum;CL Willman Blood 94(3):1086-1099

CPG island methylator phenotype in acute myelogenous leukemia

M Toyota;KJ Kopecky;M Ohe-Toyota;C Willman;JPJ Issa Blood 94(10)Suppl.1:491a(#2196)part_1_of_2

Methylation analysis of the human multidrug resistance 1 gene in normal and leukemic hematopoietic cells

KB Fryxell;SB McGee;DK Simoneaux;CL Willman;MM Cornwell Leukemia 13:910-917

P73 mutations and expression in adult de novo acute myelogenous leukemia

DL Stirewalt;B Clurman;FR Appelbaum;CL Willman;JP Radich Leukemia 13:985-990

Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony-stimulating factor fusion protein.

DE Hogge;CL Willman;RJ Kreitman;M Berger;PD Hall;KJ Kopecky;C McLain;EP Tagge;CJ Eaves;AE Frankel Blood 92(2):589-595

Cell cycle arrest and therapeutic sensitivity in de novo AML.

D Banker;C Willman;M Groudine;F Appelbaum Blood 90(10)Suppl.1:67a(#290)

Estrogen receptor methylation is associated with improved survival in adult acute myeloid leukemia (AML).

Q Li;KJ Kopecky;A Mohan;F Appelbaum;SB Baylin;C Willman;J Issa Proc of the American Society of Clinical Oncology 16:4a(#11)

Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.

DE Banker;M Groudine;T Norwood;FR Appelbaum Blood 89(1):243-255

Long-term survival after chemotherapy for acute myeloid leukemia: The experience of the Southwest Oncology Group.

FR Appelbaum;KJ Kopecky Cancer 80:2199-2204

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study.

JK Weick;KJ Kopecky;FR Appelbaum;DR Head;LL Kingsbury;SP Balcerzak;JN Bickers;HE Hynes;JL Welborn;SR Simon;M Grever Blood 88(8):2841-2851

Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia.

L Pearson;CP Leith;MH Duncan;IM Chen;T McConnell;K Trinkaus;K Foucar;CL Willman Leukemia 10:1274-1282

Estrogen receptor methylation is a favorable prognostic factor in AML.

JJ Issa;KJ Kopecky;F Appelbaum;C Willman;SB Baylin American Society of Clinical Oncology 15:357(#1048)

Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia.

T Nakamura;DA Largaespada;MP Lee;LA Johnson;K Ohyashiki;K Toyama;SJ Chen;CL Willman;IM Chen;AP Feinberg;NA Jenkins;NG Copeland;JD Shaughnessy Jr Nature Genetics 12:154-158

Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations.

WT Beck;TM Grogan;CL Willman;C Cordon-Cardo;DM Parham;JF Kuttesch;M Andreff;SE Bates;CW Berard;JM Boyett;NA Brophy;HJ Broxterman;HSL Chan;WS Dalton;M Dietel;AT Fojo;RD Gascoyne;D Head;PJ Houghton;DK Srivastava;M Lehnert;CP Leith;E Paietta;ZP Pavelic;L Rimsza;IB Roninson;BI Sikic;PR Twentyman;R Warnke;R Weinstein Cancer Research 56:3010-3020

Identification of the chimeric protein product of the CBFB-MYH11 fusion gene in inv(16) leukemia cells.

PP Liu;C Wijmenga;A Hajra;TB Blake;CA Kelley;RS Adelstein;A Bagg;J Rector;J Cotelingam;CL Willman;FS Collins Genes Chromosomes and Cancer 16:77-87

Spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.

DE Banker;M Groudine;FR Appelbaum Blood 88(10)Suppl:665a(#2649)

Characterization and rapid diagnostic utility of a novel antibody detecting the CBFB/SMMHC fusion protein of inversion(16)/t(16;16) associated acute myeloid leukemia.

DS Viswanatha;IM Chen;PP Liu;ML Slovak;C Rankin;CL Willman Blood 88(10)Suppl:664a(#2646)

The biological significance of the multidrug resistance gene MRP in inversion 16 leukemias.

BJ Kuss;RG Deeley;SPC Cole;CL Willman;KJ Kopecky;SR Wolman;HJ Eyre;DF Callen Leukemia and Lymphoma 20:357-364

Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia.

D Head;KJ Kopecky;J Weick;JC Files;D Ryan;K Foucar;M Montiel;J Bickers;A Fishleder;M Miller;C Spier;C Hanson;M Bitter;R Braziel;G Mills;J Welborn;W Williams;J Hewlett;C Willman;FR Appelbaum Blood 86(5):1717-1728

Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: Identification of discordant MDR-/efflux+ and MDR1+/efflux- cases

CP Leith;IM Chen;KJ Kopecky;FR Appelbaum;DR Head;JE Godwin;JK Weick;CL Willman Blood 86(6):2329-2342

Genetic heterogeneity of acute myeloid leukemia (AML) with FAB-AML M3 morphology

DR Head;F Behm;S Raimondi;A Carroll;M Slovak;E Magenis;C Willman;J Licht;A Scott;MV Gresik;J Downing;D Butler;T Motroni International Academy of Pathology Book of Abstracts :112A(#651)

Heterogeneity in CBFB/MYH11 fusion messages encoded by inv(16) and t(16;16) in acute myelogenous leukemia (AML)

J Downing;S Shurtleff;S Meyers;S Hiebert;S Raimondi;D Head;C Willman;S Wolman;A Carroll;F Behm;F Collins;P Liu International Academy of Pathology Book of Abstracts :109A(#630)

Amplification of the E2F-1 transcription factor gene in the HEL erythroleukemia cell line

M Saito;K Helin;MB Valentine;BB Griffith;CL Willman;E Harlow;AT Look Genomics 25:130-138

Heterogeneity in CBF'/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia

SA Shurtleff;S Meyers;SW Hiebert;SC Raimondi;D Head;CL Willman;SR Wolman;ML Slovak;AJ Carroll;F Behm;MG Hulshof;TA Motroni;T Okuda;P Liu;FS Collins;JR Downing Blood 85(12):3695-3703

Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia.

B Mehrotra;TI George;K Kavanau;H Avet-Loiseau;D Moore II;Cl Willman;ML Slovak;S Atwater;DR Head;MG Pallavicini Blood 86(3):1139-1147

Trisomy 11: an association with stem/progenitor cell immunophenotype.

ML Slovak;ST Traweek;CL Willman;DR Head;KJ Kopecky;RE Magenis;FR Appelbaum;SJ Forman British Journal of Hematology 90:266-273

Multidrug resistance (MDR1) expression and function in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR).

CP Leith;KJ Kopecky;IM Chen;JE Godwin;FR Appelbaum;DR Head;CL Willman Leukemia 9(3):535(#O31)

Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group.

EL Sievers;FO Smith;WG Woods;JW Lee;WA Bleyer;CL Willman;ID Bernstein Leukemia 9:2042-2048

Consistent loss of the D5S89 locus mapping telomeric to the interleukin gene cluster and centromeric to EGR-1 in patients with 5q- chromosome

L Nagarjan;J Zavadil;D Claxton;X Lu;J Fairman;J Warrington;JJ Wasmuth;AC Chinault;CE Sever;ML Slovak;CL Willman;AB Deisseroth Blood 83(1):199-208

CD56: A determinant of extramedullary and central nervous system (CNS) involvement in acute myeloid leukemia (AML). Modern Pathology 7(1):120A (#695)

AA Scott;KJ Kopecky;TM Grogan;DR Head;FA Troy, II;J Mullen;J Ya;FR Appelbaum;KS Theil;CL Willman Intl Academy of Pathology 120A(#695)/Lab Investigation 70(1):120A(#695)

Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) experience.

DR Head;KJ Kopecky;C Willman;FR Appelbaum Leukemia 8(Suppl.2):S38-S41

HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: A previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3

AA Scott;DR Head;KJ Kopecky;FR Appelbaum;KS Theil;MR Grever;I-M Chen;MH Whittaker;BB Griffith;JD Licht;S Waxman;MM Whalen;AD Bankhurst;LC Richter;TM Grogan;CL Willman Blood 84(1):244-255

Trisomy 8: A primary cytogenetic anomaly in leukemia?

SR Wolman;ML Slovak;CL Willman;FR Appelbaum;RE Magenis Blood 84(10)(Suppl.1):308a(#1219)

Comparative genomic hybridization (CGH) and cytogenetics provide complementary information to identify genetic abnormalities in AML.

H Avet-Loiseau;K Thiel;T McConnell;CL Willman;S Atwater;MG Pallavicini Blood 84(10)(Suppl.1)(#2380):599a

Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia (AML).

L Pearson;CP Leith;I-M chen;MH Duncan;T McConnell;K Theil;K Foucar;CL Willman Blood 84(10)(Suppl.1)(#172):46a

Correlation of functional efflux and multidrug resistance (MDR1) expression in acute myeloid leukemia (AML) in the elderly: MDR1 and secondary AML status are independent predictors of complete remission (CR).

CP Leith;KJ Kopecky;I-M Chen;JE Godwin;FR Appelbaum;DR Head;CL Willman Blood 84(10)(Suppl.1)(#1493):377a

Deletion of gene for multidrug resistance in acute myeloid leukemia with inversion in chromosome 16: prognostic implications

BJ Kuss;RG Deeley;SPC Cole;CL Willman;KJ Kopecky;SR Wolman;HJ Eyre;SA Lane;JK Nancarrow;SA Whitmore;DF Callen Lancet 343:1531-1534

Acute promyelocytic leukemia associated wit t(11;17) is a discrete syndrome that fails to respond to retinoic acid.

JD Licht;C Chomienne;A Goy;A Chen;AA Scott;DR Head;JL Michaux;Y Wu;A DeBlasio;WH Miller Jr;AD Zelenetz;CL Willman;Z Chen;A Zelent;E Macintyre;A Veil;J Cortes;H Kantarjian;S Waxman Blood 84(10)(Suppl.1)(#1500):379a

Reply to comments by Fenaux and Warrell.

DR Head;KJ Kopecky;C Willman;FR Appelbaum Leukemia 8(Suppl.2):S62

An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the t(8;21) (q22;q22).

JR Downing;DR Head;AM Curcio-Brint;MG Hulshof;TA Motroni;SC Raimondi;AJ Carroll;HA Drabkin;CL Willman;KS Theil;CI Civin;P Erikson Blood 81(11):2860-2865

HRX involvement in de novo and secondary leukemias with diverse chromosome 11q23 abnormalities.

SP Hunger;DC Tkachuk;MD Amylon;MP Link;AJ Carroll;Jl Welborn;CL Willman;ML Cleary Blood 81(12):3197-3203

Identification and characterization of a previously unrecognized form of acute leukemia co-expressing myeloid and natural killer (NK) cell-associated antigens (CD56).

AA Scott;DR Head;K Theil;LM Chen;MH Whittaker;CL Willman International Academy of Pathology 68:100A(#575)

Clinical significance and functional analysis of the expression of the multidrug resistance gene (MDR1) in acute myeloid leukemia (AML).

CP Leith;LM Chen;BB Griffith;DR Head;AF List;FR Appelbaum;CL Willman International Academy of Pathology 68:94A(#544)

Functional assessment of the multidrug (MDR1) resistance efflux pump in acute myeloid leukemia (AML): Identification of CD34-, CD33+, MRK16+ (MDR1+) cases lacking functional dye efflux.

CP Leith;KJ Kopecky;IM Chen;BB Griffith;FR Appelbaum;CL Willman Blood 82(10)(Suppl.1):(#1754)

Clinical and molecular characterization of the acute promyelocytic leukemia (APL) associated with the t(11;17) and PLZF-RAR fusion.

Z Chen;JD Licht;A Zelent;SJ Chen;A Chen;Y Wu;WH Miller Jr;A Zelenetz;A Goy;A DeBlasio;A Scott;C Willman;D Head;C Chomienne;F Guidez;S Waxman Blood 82(10)(Suppl.1):(#432)

Development of a highly sensitive ploymerase chain reaction detect allele loss in the 5q-chromosome.

J Fairman;D Claxton;C Willman;A Deisseroth;L Nagarajan Blood 82(10)(Suppl.1)(#123)

N-ras mutations in acute myelogenous leukemia: A review of the current literature and an update of the Southwest Oncology Group experience.

JP Radich;KJ Kopecky;F Appelbaum;CL Willman;SJ Collins Leukemia and Lymphoma 6:325-334

False positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts.

S Betz;K Foucar;DR Head;IM Chen;CL Willman Blood 79:2399-2403

Activation of EVI-1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26.

K Morishita;E Paraganas;CL Willman;MH Whittaker;H Drabkin;J Oval;R Taetle;MB Valentine;JN Ihle Proc Natl Acad Sci 89:3937-3941

A randomized investigation of high-dose (HDAC) versus standard dose (SDAC) cytosine arabinoside with daunorubicin (DNR) in patients with acute myelogenous leukemia.

J Weick;K Kopecky;FR Appelbaum;D Head;L Elias;L Kingsbury;D Daniels;SP Balcerzak;GM Mills;HE Hynes;CA Coltman Jr;M Grever ASCO 11:261(#856)

Biologic parameters that predict treatment response in de novo acute myeloid leukemia (AML): CD34, but not multidrug resistance (MDR) gene expression, is associated with a decreased complete remission (CR) rate and CD34+ patients more frequently achieve CR with high dose cytosine arabinoside.

CL Willman;KJ Kopecky;J Weick;FR Appelbaum;MR Grever;DR Head;L Elias;SP Balcerzak;GM Mills;HE Hynes ASCO 11:262(#857)

Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin-A (CSA).

AF List;C Spier;J Greer;C Azar;J Hutter;S Wolff;S Salmon ASCO 11:264(#866)

Chromosomal rearrangements 3' of the EV1 myeloid transforming gene activate expression in human acute myelogenous leukemia.

A Gajiar;E Parganas;CL Willman;K Morishita;J Ihle Blood 80(10)Suppl.1:256a

Interferon regulatory factor-1 (IRF-1): A candidate tumor suppressor gene on chromosome 5q31-1 deleted in leukemia and myelodysplasia (MDS) with del (5q) or translocation of 5q31.

CL Willman;C Sever;M Pallavicini;H Harada;N Tanaka;M Slovak;A List;H Yamamoto;K Harada;T Taniguchi Blood 80:74a(#286)

The human cell cycle gene CDC25C maps to chromosome 5q31.1 within 100 KB of interferon regulatory factor-1 (IRF-1) in the critical region deleted in myelodysplasia (MDS) and leukemia with 5q abnormalities.

C Sever;CL Willman;H Harada;T Taniguchi;W Kuo;M Pallavicini;M Slovak;T Meeker Blood 80(10)-Suppl.1:195a(#769)

Evaluation of the proliferative fraction of cytogenetically normal and aberrant hemopoietic subpopulations in acute myeloid leukemia (AML and myelodysplasia (MDS).

TI George;B Mehrotra;CL Willman;PI Greenberg;MG Pallavicini Blood 80(10)-Suppl.1:30a

Variable frequency of cytogenetically aberrant cells in the stem cell compartment and hemopoietic lineages in acute myeloid leukemia (AML) and myelodysplasia (MDS).

B Mehrotra;C Mar;WL Kuo;CL Willman Blood 80(10)-Suppl.1:30a

Precise localization of the long arm breakpoint of the inv(16) of ANNL M4Eo and progress towards cloning this breakpoint.

D Callen;B Kuss;CL Willman;H Eyre;J Nancarrow;N Lapsys;RI Richards;GR Sutherland Am J Human Genetics 51(4):57A

Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages.

CL Willman;CC Stewart;TL Longacre;DR Head;R Habbersett;SF Zeigler;RM Perlmutter Blood 77(4):726-734

Multiparameter analysis of the expression of the multidrug resistance genes MDR1 and MDR2 (MDR3) in de novo AML by polymerase chain reaction (PCR) and multicolor flow cytometry: Identification of a biological subset of CD34+, MDR1 + AML cases.

CL Willman;K Kopecky;B Griffith;IM Chen;K Noonan;I Roninson;DR Head;T Tsuruo;J Weick;M Grever;F Appelbaum Blood 78:172a

Multidrug resistance in CD34+ acute leukemia correlates with non-lymphoid lineage.

C Spier;A List;CL Willman;F Appelbaum;C Karanes;D Head Blood 78:175a

Multiparameter analysis of acute mixed lineage leukemia: Correlation of aB/Myeloid immunophenotype and immunoglobulin and T-cell gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with

IA Saikevych;DP Kerrigan;TS McConnell;DR Head;FR Appelbaum;CL Willman Leukemia 5(5):373-382

Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction.

KE Noonan;C Beck;TA Holzmayer;JE Chin;JS Wunder;IL Andulis;AF Gazdar;CL Willman;BB Griffith;DD Von Hoff;IB Roninson Proceedings National Academy of Science USA 87:7160-7164

N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance.

JP Radich;KJ Kopecky;CL Willman;J Weick;D Head;F Appelbaum;SJ Collins Blood 75(4):801-807

Cloning and characterization of the (15;17) translocation break point region in acute promyelocytic leukemia.

RS Lemons;D Eilender;R Waldmann;M Rebentisch;A Frej;D Ledbetter;C Willman;T McConnell;P O'Connell Genes Chromosomes and Cancer 2:79-87

The molecular biology of acute myeloid leukemia. Proto-oncogene expression and function in normal and neoplastic myeloid cells.

CL Willman;MH Whittaker Clinics in Laboratory Medicine 10(4):769-796

Analysis of MDR1 gene expression in clinical tumor samples by polymerase chain reaction (PCR).

KE Noonan;C Beck;TA Holzmeyer;J Wunder;I Andrulis;C Willman;B Griffith;DD Von Hoff;IB Roninson AACR 31:361(#2140)

Expression of the EVI-1 gene encoding a DNA-binding protein in AMLs with karyotypic abnormalities of chromosome 3q.

M Whittaker;K Morishita;C Willman;T McConnell;J Lewis;J Ihle Laboratory Investigation/Modern Pathology 62:106a

Multiparameter analysis of acute mixed lineage leukemia: Correlation of B/Myeloid immunophenotype and immunoglobulin and T-cell gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology.

IA Saikevych;DP Kerrigan;TS McConnell;D Head;FR Appelbaum;CL Willman Leukemia 5(5):373-382

Biological parameters associated with therapeuticnon-responsiveness in a cute myeloid leukemia (AML).

C Willman;L Elias;B Griffith;L Dressler;E Erickson-Ford;D Head;K Kopecky;D Stock-Novack;J Weick;M Grever ASCO 8:200(#777)